STOCK TITAN

Exagen Inc - XGN STOCK NEWS

Welcome to our dedicated news page for Exagen (Ticker: XGN), a resource for investors and traders seeking the latest updates and insights on Exagen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Exagen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Exagen's position in the market.

Rhea-AI Summary
Exagen Inc. (Nasdaq: XGN) reported strong financial results for the fourth quarter and full year ended December 31, 2023, with record total revenue of $52.5 million for 2023. The company performed 137,650 AVISE® CTD tests in 2023, showing a significant increase in ASP. Despite a net loss of $23.7 million for the full year, Exagen is focused on profitability, expense reduction, and managing cash effectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.26%
Tags
earnings
-
Rhea-AI Summary
Exagen Inc. (XGN) to participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, offering one-on-one meetings with investors and a fireside chat on March 20, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
conferences
-
Rhea-AI Summary
Exagen Inc. (Nasdaq: XGN) will release financial results for Q4 and full year 2023 on March 18, 2024. Conference call with the CEO and CFO to review results on the same day at 8:30 AM ET. Webcast and replay details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
earnings
Rhea-AI Summary
Exagen Inc. (Nasdaq: XGN) will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13-14, 2024, in Snowbird, Utah. Exagen's President and CEO, John Aballi, and CFO, Kamal Adawi, will hold one-on-one meetings with investors during the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.52%
Tags
conferences
-
Rhea-AI Summary
Exagen Inc. (XGN) Announces Preliminary Financial Results and Reaffirms Full-Year 2023 Guidance
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Summary
Exagen Inc. (Nasdaq: XGN) reported Q3 2023 financial results, including $13.4 million in revenue, a gross margin of 57.4%, and a net loss of $(5.4) million. The company also entered an exclusive license agreement with Johns Hopkins University and provided guidance for at least $50 million in record annual revenue for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.44%
Tags
earnings
Rhea-AI Summary
Exagen Inc. (Nasdaq: XGN) and Johns Hopkins University announced an exclusive license agreement to develop novel patented biomarkers for therapeutic management of lupus nephritis patients. The agreement grants Exagen worldwide exclusive rights to an invention from the laboratory of Michelle Petri, MD, MPH, and Andrea Fava, MD. The biomarkers aim to provide unique clinical insight into a patient’s lupus nephritis in a non-invasive manner, aiding diagnostic and treatment decisions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
none
-
Rhea-AI Summary
Exagen Inc. (Nasdaq: XGN) will participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 16th, 2023. Exagen's President and CEO, John Aballi, and CFO, Kamal Adawi, will present at 9:30 AM ET. The webcast of the presentation can be accessed on Exagen's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
conferences
-
Rhea-AI Summary
Exagen Inc. will release its financial results for Q3 2023 on November 13, 2023. The conference call to review the results will be hosted by the President and CEO, John Aballi, and the CFO, Kamal Adawi. Interested parties can access the call via dial-in or webcast. A replay of the call will be available until November 27, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.08%
Tags
earnings
Rhea-AI Summary
Exagen Inc. accepted five abstracts at the ACR Convergence 2023, showcasing their autoimmune testing solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
Exagen Inc

Nasdaq:XGN

XGN Rankings

XGN Stock Data

27.40M
7.10M
30.42%
59.61%
0.03%
Dental Laboratories
Manufacturing
Link
US
Vista

About XGN

exagen diagnostics, inc. is a patient focused, discovery driven, clia-certified, cap-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. committed to personalized medicine, our avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. for more information on our company, please visit www.exagen.com. for more information on avise testing services, please visit www.avisetest.com.